SNSE stock is currently trading at $0.6633, significantly below its 52-week high. Bulls argue that the stock has a strong upside potential, with HC Wainwright maintaining a "Strong Buy" rating and a price target of $4, implying a 680% upside. This optimism is driven by the company's progress in its SNS-101 trial targeting the VISTA checkpoint and its extended cash runway to mid-2026, positioning it well for future growth in oncology.